CS
ITOS

Candriam SCA’s iTeos Therapeutics ITOS Stock Holding History

Candriam SCA’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-769,213
Closed -$7.85M – 690
2024
Q3 		$7.85M Buy
769,213
+259,910
+51% +$3.97M 0.05% 299
2024
Q2 		$7.56M Buy
+509,303
New +$7.3M 0.05% 288
2023
Q4 		– Sell
-511,537
Closed -$5.6M – 714
2023
Q3 		$5.6M Sell
511,537
-100,010
-16% -$1.28M 0.04% 298
2023
Q2 		$8.1M Sell
611,547
-127,970
-17% -$1.82M 0.06% 270
2023
Q1 		$9.26M Hold
739,517
– – 0.06% 269
2022
Q4 		$14.4M Hold
739,517
– – 0.1% 210
2022
Q3 		$14.1M Sell
739,517
-48,134
-6% -$1.11M 0.1% 211
2022
Q2 		$16.2M Buy
787,651
+103,839
+15% +$2.46M 0.13% 166
2022
Q1 		$22M Sell
683,812
-73,515
-10% -$2.67M 0.15% 156
2021
Q4 		$35.3M Buy
757,327
+232,083
+44% +$7.73M 0.23% 117
2021
Q3 		$14.2M Buy
525,244
+20,354
+4% +$532K 0.1% 223
2021
Q2 		$13M Buy
504,890
+504,872
+2,804,844% +$12M 0.09% 248
2021
Q1 		$1K Buy
+18
New +$650 ﹤0.01% 799

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Candriam SCA's ITOS Position: Q4 2024 in Review

Candriam SCA sold out of iTeos Therapeutics (ITOS) in Q4 2024, closing a stake of 769,213 shares — an estimated $7.85M sold.

Candriam SCA first reported a position in ITOS in Q1 2021 and held it in 13 quarters. The position peaked at $35.3M in Q4 2021. 136 funds tracked by Wall St. Rank hold ITOS as of Q4 2024.

  • Candriam SCA reported no remaining iTeos Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Candriam SCA sold 769,213 iTeos Therapeutics shares in Q4 2024, an estimated $7.85M.
  • Candriam SCA first reported a position in iTeos Therapeutics in Q1 2021 and held it in 13 quarters.
  • Candriam SCA's iTeos Therapeutics position peaked at $35.3M in Q4 2021.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2024.

Based on Candriam SCA's 13F filing for Q4 2024, filed 7 Feb 2025.